U. PITTSBURGH (US) — A coverage gap in Medicare Part D increases costs and health risks for people suffering from schizophrenia and bipolar disorder, a new study shows. Published in the American Journal of Managed Care, the research finds that in Medicare Part D, generic drug coverage was cost-saving compared to no coverage in bipolar disorder and schizophrenia, while also improving health outcomes.